摘要
目的探讨HBeAg阳性与HBeAg阴性慢性乙型肝炎(CHB)患者停用核苷(酸)类似物(NUC)抗病毒治疗后肝炎复发致HBV相关慢加急性肝衰竭(HBV-ACLF)的临床病情转归的差异及可能的原因。方法选取2017年1月—2018年12月于南昌大学第一附属医院收治的108例停用NUC后致HBV-ACLF的CHB患者。根据HBeAg状态分为HBeAg阳性组(n=57)和HBeAg阴性组(n=51),分析比较两组患者性别、年龄、临床表现、体征和入院时TBil、DBil、ALT、AST、PT、活化部分PT(APTT)、PT/INR、HBV DNA定量检测结果,以及并发症(肝性脑病、肝肾综合征、自发性腹膜炎等)情况、HBV-ACLF病情转归差异。同时,选取48例持续NUC抗病毒治疗>2年且HBV DNA<20 IU/mL的CHB患者,收集并检测其血清HBV pgRNA水平,探讨影响停药时不同HBeAg状态患者HBV-ACLF预后差异的可能原因。符合正态分布的计量资料两组间比较采用两独立样本t检验;不符合正态分布的计量资料两组间比较采用Kruskal-Wallis H检验。计数资料两组间比较采用χ^(2)检验。结果在108例停药复发HBV-ACLF患者中,HBeAg阳性组好转率49.1%,HBeAg阴性组好转率74.5%。HBeAg阴性组的好转率高于HBeAg阳性组,差异有统计学意义(χ^(2)=2.811,P=0.006)。HBeAg阳性组入院时HBV DNA水平明显高于HBeAg阴性组,差异有统计学意义(t=-3.138,P=0.002)。在48例长期NUC抗病毒治疗达到病毒学应答的CHB患者中,HBeAg阳性组HBV pgRNA载量明显高于HBeAg阴性组(H=2.814,P=0.049)。结论HBeAg阴性CHB患者停用NUC抗病毒治疗后肝炎复发致HBV-ACLF的病情好转率高于HBeAg阳性患者。基线HBV pgRNA水平差异可能与不同HBeAg状态HBV-ACLF的病情转归存在差异有关。
Objective To investigate the difference in the prognosis of hepatitis B virus-related acute-on-chronic liver failure(HBV-ACLF)caused by hepatitis recurrence after withdrawal of nucleos(t)ide analogues(NUC)and possible causes in HBeAg-positive versus HBeAg-negative chronic hepatitis B(CHB)patients.Methods A total of 108 CHB patients with HBV-ACLF caused by withdrawal of NUC who were admitted to The First Affiliated Hospital of Nanchang University from January 2017 to December 2018 were enrolled,and according to HBeAg status,these patients were divided into HBeAg-positive group with 57 patients and HBeAg-negative group with 51 patients.The two groups were compared in terms of sex,age,clinical manifestation,signs,levels of total bilirubin,direct bilirubin,alanine aminotransferase,aspartate aminotransferase,prothrombin time,activated partial thromboplastin time,prothrombin time/international normalized ratio,and HBV DNA quantification on admission,complications(including hepatic encephalopathy,hepatorenal syndrome,and spontaneous bacterial peritonitis),and prognosis of HBV-ACLF.In addition,48 CHB patients with continuous NUC antiviral therapy for>2 years and HBV DNA<20 IU/mL were enrolled,and the serum level of HBV pgRNA was measured to investigate the possible causes of the difference in the prognosis of HBV-ACLF between the patients with different HBeAg statuses.The two-independent-samples t test was used for comparison of normally distributed continuous data between two groups,and the Kruskal-Wallis H test was used for comparison of non-normally distributed continuous data between two groups;the chi-square test was used for comparison of categorical data.Results For the 108 patients with HBV-ACLF caused by drug withdrawal and recurrence,the HBeAg-positive group had an improvement rate of 49.1%and the HBeAg-negative group had an improvement rate of 74.5%.The HBeAg-negative group had a significantly higher improvement rate than the HBeAg-positive group(χ^(2)=2.811,P=0.006).The HBeAg-positive group had a significant
作者
沈佳聪
李小鹏
程晓宇
车媛梅
雷弯
周观林
张伦理
SHEN Jiacong;LI Xiaopeng;CHENG Xiaoyu;CHE Yuanmei;LEI Wan;ZHOU Guanlin;ZHANG Lunli(Department of Infectious Diseases,Shaoxing People’s Hospital,Shaoxing,Zhejiang 312000,China;Center for Diagnosis and Treatment of Infectious Diseases,The First Affiliated Hospital of Nanchang University,Key Laboratory of Liver Regeneration of Jiangxi Province,Nanchang 330006,China;Department of Science and Technology,The First Affiliated Hospital of Nanchang University,Nanchang 330006,China;Department of Hepatology,Ganzhou Fifth People’s Hospital,Ganzhou,Jiangxi 341099,China)
出处
《临床肝胆病杂志》
CAS
北大核心
2022年第1期86-90,共5页
Journal of Clinical Hepatology
基金
江西省卫健委科技计划(指导性计划)项目(202140689)
江西省科技厅计划项目(20212BAG70022)
南昌大学教改课题(NCUJGLX-2020-166-162)。
关键词
肝炎
乙型
慢性
肝炎e抗原
乙型
慢加急性肝衰竭
核苷类
核苷酸类
Hepatitis B,Chronic
Hepatitis B e Antigens
Acute-On-Chronic Liver Failure
Nucleosides
Nucleotides
